HAE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available capital, Haemonetics Corp (HAE) does not present a compelling buy opportunity at this moment. The stock lacks strong positive catalysts, has mixed analyst ratings, and its technical indicators suggest a neutral trend. Additionally, recent financial performance shows revenue decline, despite improvements in net income and EPS. It is better to wait for clearer positive signals or stronger growth indicators before investing.
The MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 62.51, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level (63.089) with resistance at 65.366 and support at 60.812. Overall, the technical indicators point to a neutral trend.
Net income and EPS showed strong YoY growth in Q3 2026, with gross margin also improving. Analysts maintain an Outperform rating despite lowering price targets, indicating some long-term confidence.
Analysts have broadly lowered price targets, and there is no recent news or significant trading activity from insiders or hedge funds to suggest strong momentum. Options data shows low put-call ratios, indicating limited speculative interest.
In Q3 2026, revenue dropped by 2.75% YoY to $338.97M. However, net income increased by 19.33% YoY to $44.74M, and EPS rose by 28.38% YoY to 0.95. Gross margin improved by 6.77% to 56.47%. While profitability metrics are improving, the revenue decline is a concern.
Analysts have mixed views, with most maintaining Outperform ratings but lowering price targets. Recent price targets range from $75 to $94, reflecting cautious optimism. The stock's performance is seen as a 'mixed bag' with potential upside in plasma markets but concerns about overall growth.
